ENT Healthcare
Market Overview

ENT Market Overview

ENT Treatment Market Overview

- Otolaryngology, or (“ENT”), is a medical specialty focused on the diagnosis and treatment of diseases that affect the ear, nose, sinus, throat, head, and neck.
- Diagnosis and treatment takes place in hospitals, clinics, or ambulatory surgical centers (“ASCs”).
  - CMS continues to approve new procedures to be performed in an ambulatory setting.
- Otolaryngologists are trained in both medicine and surgery and can address cosmetic issues as well as health issues.
- Market demand for Otolaryngologists is driven by an:
  - Increasing rate of hearing loss
  - Expansion of healthcare coverage
  - Aging population consumes more healthcare services
  - Increasing incidence of allergies and related ailments

Key ENT Stats

- 466 million People worldwide have disabling hearing loss
- 34 million Of which are children
- 27 million People see an ENT doctor each year in the U.S., generating
- $6.2 billion Of ENT Treatment Market Value
- 31 million People in the U.S. are afflicted by sinusitis
- 16 million Doctor visits for sinusitis in the U.S.
- 59.0% Of ENT Patients are Privately Insured
- $2,492 Median net revenue per ENT case at ASCs

Global ENT Treatment Market Growth, 2020-2030

($ in billions)

<table>
<thead>
<tr>
<th>Year</th>
<th>Ear Infections</th>
<th>Ear Noise (Tinnitus)</th>
<th>Facial &amp; Cranial Nerve Pain/D</th>
<th>Congenital Disorders</th>
<th>Nose Infections</th>
<th>Nasal Cavity Allergies</th>
<th>Sinusitis</th>
<th>Throat Tumors</th>
<th>Diseases of the Larynx (Voice Box)</th>
<th>Voice Disorders</th>
<th>Swallowing Disorders</th>
<th>Infectious Diseases</th>
<th>Facial Trauma</th>
<th>Benign &amp; Malignant Tumors</th>
<th>Deformities of the Face</th>
<th>Thyroid Conditions</th>
<th>Free Flap Reconstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>$15.2</td>
<td>$16.2</td>
<td>$17.2</td>
<td>$18.2</td>
<td>$19.4</td>
<td>$20.6</td>
<td>$21.9</td>
<td>$23.3</td>
<td>$24.7</td>
<td>$26.3</td>
<td>$28.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sources: Becker ASC, Precedence Research, World Health Organization.
ENT Healthcare
Market Overview

ENT Market Demand Drivers

Increasing Rates of Hearing Loss

Global

- The World Health Organization ("WHO") predicts the global population with hearing loss will grow from 466 million in 2018 to 900 million by 2050, making hearing impairment one of the most common disabilities in the world
- Chronic Otitis Media ("Ear Infection") is the leading cause of hearing loss globally
  - This disease is preventable, but the number of global cases is increasing due to incredibly low accessibility to ENT treatment in developing nations

North America

- 10.0% of North Americans are plagued by loss of hearing
- Hearing loss in the U.S. increased from 11.5 million incidences in 2008 to nearly 15.0 million incidences in 2018

Increased Levels of Health Insurance Coverage

% of Uninsured Americans

<table>
<thead>
<tr>
<th>Q4 2020</th>
<th>Q1 2021</th>
<th>Q2 2021</th>
<th>Q3 2021</th>
<th>Q4 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.3%</td>
<td>9.5%</td>
<td>9.7%</td>
<td>8.9%</td>
<td>8.8%</td>
</tr>
</tbody>
</table>

- The Biden Administration has an explicit goal to expand health coverage
  - Medicare and Medicaid spending is projected to grow at an average annual rate of 7.2% and 5.6%, respectively through 2030
  - Over 14.5 million Americans signed up for health coverage since 2020
- Without health insurance, visiting otolaryngologists in an emergency can cost up $500
  - Increased insurance coverage makes ENT Treatment more accessible and thus in higher demand

Increasing Geriatric Population Size

% of U.S. Population with Hearing Loss by Age

<table>
<thead>
<tr>
<th>Age 20-29</th>
<th>Age 30-39</th>
<th>Age 40-49</th>
<th>Age 50-59</th>
<th>Age 60-69</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8%</td>
<td>0.9%</td>
<td>3.4%</td>
<td>11.2%</td>
<td>24.7%</td>
</tr>
</tbody>
</table>

- The WHO reports that the proportion of the world population over 60 years will go from 12.0% today to 22.0% by 2050
- ENT issues progress with age and create challenges for the elderly which contribute to the deterioration of mobility, falls and injuries, depression, cognitive functions impairments, isolation, and a loss of independence

Allergy Growth Drivers Mirror Those of the ENT Treatment Market

- Increased healthcare coverage through Medicare and Medicaid
  - Encourages more individuals to seek out help related to allergy health issues
- Increasing size of geriatric population
  - Elderly people are often immunocompromised
  - Leaves them susceptible to various types of allergies and in need of treatment
- Increase in the prevalence of allergic disorders due to a more hygienic lifestyle

Too Few Otolaryngologists in the U.S.

- There are approximately 10,000 fully trained and practicing otolaryngologists in the U.S.
- Most research suggests that the number of trained otolaryngologists is insufficient to supply current and projected U.S. healthcare needs
  - Experts cite a need for a change in training such as mandating earlier commitment to sub-specialization and shortening the length of residency
  - There have been calls for Congress to lift the cap on the number of residency positions that Medicare partially supports
  - The shortage of otolaryngologists is becoming more acute as improvements in technology and surgical applications increase demand

Distribution of Otolaryngologists Across U.S. Treatment Facilities

- **5,961** otolaryngologists in the U.S. practice in cities and metropolitan areas
- **65.7%** of U.S. counties do not have access to ENT healthcare facilities

Distribution of ENT Doctors Across Regions

- The supply of and competition between otolaryngologists increases with regional population, income, education, and socioeconomic status
- North America holds the largest share of the global ENT market due to the continent’s relatively:
  - Increased health consciousness
  - Rising healthcare expenditure & insurance coverage
  - Rapid growth of minimally invasive surgeries available in the U.S.

Most U.S. otolaryngology private clinics spend around $300,000 to $400,000 annually on supplies, services and equipment essential to treating patients

Sources: American Medical Association, Becker ASC, Fuel Medical, Geographic Distribution of the Otolaryngologist, National Library of Medicine, Otolaryngology Workforce Analysis, SCL Health.
ENT Healthcare
Market Overview

Key Trends in the ENT Market

Otolaryngologists Continue to Concentrate in Densely Populated Regions

Statistics on Rural Areas & ENT Treatment

Nearly One out of Four
Of Americans live in rural settings

61.8%
Of U.S. otolaryngology treatment facilities are located in cities and metropolitan areas

2,064
U.S. counties do not have an otolaryngologist practice. Most of these are in rural areas

98.0%
Of Head and Neck Surgeons practice in urban settings

Number of Otolaryngologists by U.S. County

Issues Associated with ENT Healthcare in Rural Locations

As technology progresses and medical practice evolves, it is difficult and costly for small-practice ENT practices to stay updated on the complicated digital components essential to enhanced treatment without a support network surrounding them

More complex procedures, such as those involving cancer removal, require support not present in many settings

Relatively more difficult to recruit ENT providers in secondary and tertiary markets

Distribution of Otolaryngologists by U.S. County Population

<table>
<thead>
<tr>
<th>Number of Counties</th>
<th>Population Range</th>
<th>Otolaryngologists</th>
</tr>
</thead>
<tbody>
<tr>
<td>733</td>
<td>≥ 75,000</td>
<td>8,949</td>
</tr>
<tr>
<td>875</td>
<td>25,000 to &lt;75,000</td>
<td>626</td>
</tr>
<tr>
<td>832</td>
<td>10,000 to &lt;25,000</td>
<td>63</td>
</tr>
<tr>
<td>702</td>
<td>&lt;10,000</td>
<td>4</td>
</tr>
</tbody>
</table>

ENT Healthcare
Market Overview

Key Trends in the ENT Market

**ENT Activity in ASCs is Poised to Grow in the Coming Years**

Key Growth Drivers of ENT Activity at ASCs

- The exponential rise in healthcare expenses over the last decade has resulted in changing healthcare practices and care settings
  - ASCs allow for significant ENT healthcare cost savings, better patient outcomes, and higher patient satisfaction scores
  - Illustratively, the cost of a tonsillectomy (removal of the tonsils performed by an otolaryngologist) in a hospital is $6,944 whereas a tonsillectomy in an ASC costs $3,433

- There is an increased frequency of ENT indications that necessitate regular minor procedures, which can be performed in ASCs instead of hospitals
  - Generally, patients spend 25.0% less time in medical care facilities when procedures are performed in ASCs versus hospitals
  - Convenience of ASCs surpasses hospitals
  - Providers and patients have more control over scheduling and face fewer delays

- There is a growing burden of performing surgical procedures on hospitals and healthcare organizations
  - Hospitals and patients cannot cost effectively allocate hospital beds in lower acuity procedures

- Ambulatory surgery centers deliver high quality results
  - Patient satisfaction rate for ASCs is 98.0%
  - Most patients find the setting to be more personal and comfortable than hospitals

ENT Treatment Provided at ASCs

- The prevalence of ASCs benefits ENTs as more procedures are added to the list of those that can be performed in an ambulatory setting
  - Illustrative procedures performed by otolaryngologists in ASCs include laryngoscopy, tonsillectomy, adenoidectomy, endoscopic sinus surgery, rhinoplasty, excisional biopsy, tympanostomy, tympanoplasty, and more

ASC Annual Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>ASC Annual Revenue ($ in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>$37,167</td>
</tr>
<tr>
<td>2021</td>
<td>$40,837</td>
</tr>
<tr>
<td>2022</td>
<td>$43,079</td>
</tr>
<tr>
<td>2023</td>
<td>$45,503</td>
</tr>
<tr>
<td>2024</td>
<td>$47,937</td>
</tr>
<tr>
<td>2025</td>
<td>$50,623</td>
</tr>
<tr>
<td>2026</td>
<td>$53,363</td>
</tr>
<tr>
<td>2027</td>
<td>$56,271</td>
</tr>
</tbody>
</table>

Number of Medicare-Certified ASCs per State/Territory

Sources: ASC Association, Becker ASC, Fierce Healthcare, Geographic Distribution of the Otolaryngologist, IBIS World.
Key Trends in the ENT Market

Increasing Preference for Minimally Invasive ENT Procedures

Evolution of ENT Surgery Procedures

**Throat**
- Otolaryngologists are most likely to recognize and diagnose laryngopharyngeal reflux disease and gastroesophageal reflux disease
  - In severe cases, ENTs will recommend surgery

**Open surgery method**: pulls the stomach down into the abdomen to allow for reconstruction of the esophageal sphincter
  - The surgeon often inserts a tube to keep the stomach in place
  - The tube is not removed for several weeks and causes discomfort

**Minimally invasive method**: laparoscopy
  - Few small incisions, use video screen and technology for the operation
  - Discomfort lasts a maximum of four days after surgery

**Ear**
- Otolaryngologists perform surgery to repair the tympanic membrane (eardrum) and remove Cholesteatoma (abnormal collection of skin cells deep inside the ear that can damage hearing and balance)

**Traditional surgery method**: incision behind the ear and possible removal of the mastoid bone
  - Six to 12 week recovery

**Minimally invasive method**: endoscopic surgery, no incision/bone removal
  - One week recovery

**Nose**
- **Traditional Rhinoplasty**: incision, bone & cartilage readjustment, bruising
  - Three month recovery, three hour operation and the nose still droops with gravity throughout aging

**Liquid Rhinoplasty**: non-invasive injectable nose reshaping dermal fillers
  - Two week recovery, 30 minute operation that lasts for a year, no blood loss

**Head & Neck**
- **Traditional Head/Neck Cancer Surgery**: Split jaw or throat to remove tumor
- **Transoral Robotic Surgery**: minimally invasive treatment that removes head and neck cancers through the mouth

Key Trends in the ENT Market

Technological Innovation Optimizes Diagnostic and Treatment Capabilities of Otolaryngologists

Revolutionized Diagnostic Capabilities Delivered Through Technology

- Technological advancement has enabled otolaryngologists to diagnose ENT disorders with increasing accuracy.
- Examples of diagnostic ENT testing performed with novel technology include:
  - Vestibular Autorotation Testing: frequently used to diagnose complex balance and vertigo disorders.
  - Ear Microscopy: Otolaryngologists can zoom in to diagnose inner ear issues.
  - Nasal Endoscopy: Endoscopes – thin, flexible tubes with a tiny camera and a light – have evolved to become increasingly effective.
    - Otolaryngologists utilize endoscopes to see inside the nose and diagnose sinus conditions.
  - Advanced Videostroboscopy: High-resolution photographs and slow motion video of a patient's vocal cords during speech which vibrate at 200 times a second.
    - This technology is used to evaluate vocal cord abnormalities, develop effective treatment plans, and observe vocal cord dynamics after surgery.

Teledmedicine in Otolaryngology

- Telehealth visits deliver care where ENT Treatment is not easily accessible, illustratively:
  - Newborns in rural areas who fail their otoacoustic emission test are a common target.
  - Rural hospitals partner with urban medical centers to give the patients access to specialized ENT treatment.
- Telehealth visits save patients' time by offering reduced wait times and enable physicians to see a larger number of patients.
- In limited instances, smart phone pictures can be used for otolaryngologists to diagnose and prescribe treatment for ENT issues.

Sources: Brandessence Market Research, Detroit Medical Center, ENT Today, SCL Health, Talk HER.
ENT Healthcare
Market Overview

ENT Subsector Overview – Allergy Treatment Market

Allergy Treatment Market Overview

- Allergic reactions occur when a person’s immune system responds to an external substance
- These reactions often trigger symptoms in the ears, nose, sinuses, and throat. Otolaryngologists are trained in the diagnosis and management of allergies as part of a broader scope of otolaryngology services
  — Some otolaryngologists specialize as ENT Allergists, and many clinics offer specialized ENT and Allergy care
- One of the more common conditions seen by ENT Allergists is allergic rhinitis, or hay fever, which causes sneezing, runny nose, and nasal stuffiness
- Other allergy conditions diagnosed and treated at ENT & Allergy care centers include food allergies and skin allergies

Key Allergy Treatment Market Statistics

- One out of Four
  People worldwide are affected by allergies, making them one of the most common health problems
- 50 million
  Or more Americans experience various types of allergies each year
- 40.0%
  Of children in the United States have allergies
- $4.0 billion
  Of revenue made by the allergy treatment market in 2021

Allergy Treatment Market Revenue Distribution by Segments

($ in millions)

<table>
<thead>
<tr>
<th>Category</th>
<th>Revenue (in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic Rhinitis</td>
<td>$1,860.8</td>
</tr>
<tr>
<td>Skin Allergies</td>
<td>$1,177.6</td>
</tr>
<tr>
<td>Food Allergies</td>
<td>$542.6</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>$438.1</td>
</tr>
<tr>
<td>Adults</td>
<td>$1,659.9</td>
</tr>
<tr>
<td>Children aged five to 11 years old</td>
<td>$1,012.8</td>
</tr>
<tr>
<td>Children aged 12 to 17 years old</td>
<td>$844.0</td>
</tr>
<tr>
<td>Children aged four and younger</td>
<td>$502.4</td>
</tr>
</tbody>
</table>

Sources: Advanced ENT & Allergy, American Academy of Allergy Asthma & Immunology, American Academy of Otolaryngic Allergy, ENT & Allergy Associates, IBIS World.
ENT Healthcare
Market Overview

Allergy Treatment Market Growth Drivers

**Increasing Need of Pediatric Care**

- Symptoms of allergies are most likely to arise during childhood
- Patients under 18 compose 58.7% of Allergy Treatment Market Revenue
- Researchers project that the number of children aged nine and younger will grow at an average rate of 0.4% in the U.S. each year from 2022 to 2026, creating significant opportunity for ENT Allergists with pediatric care capabilities

**Increasing Prevalence of Allergies**

- A number of epidemiological studies have found an increase in the prevalence of allergic disorders over the past few decades
- The CDC states that the prevalence of food allergy increased by about 50.0% between 1997 and 2011 and in 2019 affected one in 13 children
- This is hypothesized to be a consequence of a more hygienic lifestyle
  - Research suggests that the reduced microbial burden faced during childhood has made humans more susceptible to allergies

**Projected Revenue Growth in Allergy Treatment Market**

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>$4,127</td>
</tr>
<tr>
<td>2023</td>
<td>$4,182</td>
</tr>
<tr>
<td>2024</td>
<td>$4,234</td>
</tr>
<tr>
<td>2025</td>
<td>$4,368</td>
</tr>
<tr>
<td>2026</td>
<td>$4,452</td>
</tr>
<tr>
<td>2027</td>
<td>$4,532</td>
</tr>
</tbody>
</table>

**Increasing Number of Children Nine and Under in the U.S.**

<table>
<thead>
<tr>
<th>Year</th>
<th>Number (millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>39.6</td>
</tr>
<tr>
<td>2021</td>
<td>39.7</td>
</tr>
<tr>
<td>2022</td>
<td>39.9</td>
</tr>
<tr>
<td>2023</td>
<td>40.1</td>
</tr>
<tr>
<td>2024</td>
<td>40.3</td>
</tr>
<tr>
<td>2025</td>
<td>40.4</td>
</tr>
<tr>
<td>2026</td>
<td>40.6</td>
</tr>
</tbody>
</table>

Private Equity Investment in the ENT and Allergy Industry

Attractive Target Sector

- 53.8% of ENT/Allergy services are offered through physician practice groups as opposed to hospitals or health systems.
- Many of the ENT groups in the U.S. are small and independent with fewer than 25 physicians.
- 54.3% of the practices are single-specialty ENT meaning that they are not aligned with a multi-specialty practice for support or infrastructure.
- These conditions present significant opportunities for smaller groups to consolidate.
- Consolidation has the promise of improving the financial performance of smaller ENT groups who will benefit from the economies of scale and a more robust corporate infrastructure.
- Financial sponsors have been targeting physician specialties that can provide additive ancillary services — ENT/Allergy practices have a number of natural ancillary opportunities through ASCs, allergy and audiology testing, ENT Pediatric centers, and more.

Top Investors in U.S. ENT/Allergy Deals, ’20-’22YTD

<table>
<thead>
<tr>
<th>Investor</th>
<th>Investment Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHORE Capital Partners</td>
<td>5</td>
</tr>
<tr>
<td>Audax Group</td>
<td>2</td>
</tr>
<tr>
<td>Candescent Partners</td>
<td>2</td>
</tr>
<tr>
<td>Excellere Partners</td>
<td>2</td>
</tr>
<tr>
<td>NEW HARBOR Capital</td>
<td>1</td>
</tr>
<tr>
<td>BEEKMAN GROUP</td>
<td>1</td>
</tr>
</tbody>
</table>

Footprint of Top Investors in U.S. ENT/Allergy Deals

Deal activity indicates early stages of PE investment in the sector.

Sources: Epstein Becker Green, PitchBook, Vector Medical Group.
Focus at Stifel

Patrick is a senior investment banker at Stifel where he focuses on healthcare services transactions. He specializes in M&A and capital raising, working closely with key stakeholders across a range of healthcare industry sub-verticals including specialty physician groups, behavioral healthcare, and other healthcare services enabling the care of patients.

Career Background

Over the past 15+ years, Patrick has had increasingly senior roles in healthcare and investment banking. Most recently, Patrick led the Healthcare Services practice at MHT Partners. Prior to joining MHT Partners, Patrick worked for Novartis’ Molecular Diagnostics group (now part of Grifols). From 2003 to 2011, he worked for Deloitte, where he served many of the firm’s largest healthcare clients. Through these engagements, Patrick provided an array of strategic, financial, and technology advisory services to healthcare leaders at hospitals, commercial payors, technology, and life sciences companies.

Career Background

MBA, University of California – Haas School of Business
BA, Economics, Organizational Studies, University of Michigan, Ann Arbor

Selected Provider Experience

*Worked on transaction while at a previous, unaffiliated firm.
Stifel Investment Banking

Health Care Services & Health Tech Practice

Leadership

- Alena Antigua
  Managing Director
  Technology
  (312) 423-8220
  alena.antigua@stifel.com

- Kojo Appenteng
  Managing Director
  Technology
  (630) 926-2136
  appentengk@stifel.com

- Chip Bierbaum
  Managing Director
  Pharma Services
  (917) 597-5743
  bierbaumc@stifel.com

- Jim Hesburgh
  Managing Director
  Services
  (917) 302-7695
  hesburghj@stifel.com

- Patrick Krause
  Managing Director
  Services
  (415) 722-6514
  krausepa@stifel.com

- Alex Halpern
  Director
  (203) 912-4366
  halpema@stifel.com

- Ben Maddison
  UK Director
  +44 (0) 207 710 7624
  ben.maddison@stifel.com

- Harvinder Minhas
  Director
  (718) 355-0541
  minhash@stifel.com

- Charles Simon
  Director
  (757) 270-5628
  simonch@stifel.com

Sector Coverage

- **Alternate Site**
  - Labs
  - Infusion Sites
  - Physical Therapy
  - Post-Acute Care

- **Behavioral Health**
  - Autism
  - General Psychology
  - Mental Health
  - Substance Abuse

- **Health Tech**
  - Data Analytics
  - Digital Health
  - Software/SaaS
  - Tech-enabled Services

- **Payor Services**
  - Managed Care
  - PBMs
  - TPAs
  - Worker’s Compensation

- **Pharma Services**
  - Clinical Trials
  - Manufacturing
  - Marketing
  - Supply Chain

- **Physician Groups**
  - Dental Services
  - Hospital-Based
  - Multi-Site
  - Veterinary Services

Product Offering

- M&A Advisory
- Equity Capital Raising
- Debt Capital Raising
- Restructuring Advisory
- Fairness Opinions
This presentation and the information contained herein is confidential and has been prepared exclusively for the benefit and internal use of the Stifel client to whom it is directly addressed and delivered (including such client’s subsidiaries, the “Company”). In connection with the preparation and provision of these materials, Stifel has relied upon and assumed, without independent investigation or verification, the accuracy and completeness of all financial and other information that was made available, supplied, or otherwise communicated to Stifel by or on behalf of the Company and other parties which may have conflicting interests with respect to the Company. Stifel and its affiliates from time-to-time may (i) effect transactions for its own account or the accounts of its customers and financial advisory services for companies, governments and individuals. In the ordinary course of these activities, which may conflict with the interests of the Company, Stifel and its affiliates may be the subject of any engagement or transaction involving the Company; (ii) hold discussions with and provide information to potential clients and other entities regarding various market and strategic matters (including potential strategic alternatives), which entities may include potential counterparties to a transaction or strategic alternative involving the Company, and which matters may have included a possible transaction with the Company; and/or (iii) perform various investment banking, financial advisory and other services for other clients and customers who may have conflicting interests with respect to the Company.

Independence of Research
Stifel prohibits its employees from directly or indirectly offering a favorable research rating or specific price target, or offering to change a rating or price target, as consideration or inducement for the receipt of business or for compensation.

Basis of Presentation
References herein to “Stifel” collectively refer to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp. References herein to “Stifel Financial” refer to Stifel Financial Corp. (NYSE: SF), the parent holding company of Stifel and such other affiliated broker-dealer subsidiaries. Unless otherwise indicated, information presented herein with respect to the experience of Stifel also includes transactions effected and matters conducted by companies acquired by Stifel (including pending acquisitions publicly announced by Stifel), or by Stifel personnel while at prior employers.

Stifel, Nicolaus & Company, Incorporated | Member SIPC & NYSE | www.stifel.com